DCDK9-202

• Description :

  DCDK9-202 a potent CDK9 PROTAC degrader with an DC50 value of 3.5 nM. dCDK9-202 exhibits broad-spectrum anti-tumor activity and extensively disrupts the oncogenic transcriptome. dCDK9-202 can activate Caspase-3/7, increase the level of cleaved PARP, and directly induce apoptosis of tumor cells. dCDK9-202 effectively inhibits TC-71 tumor growth without any signs of toxicity in mice. dCDK9-202 can be used for the study of EGFR-driven cancers such as sarcoma (Pink: CDK9 ligand (HY-178862) ; Blue: CRBN ligand (HY-W248665) ; Black: Linker (HY-N8015) ) [1].

• UNSPSC :

  12352005

• Target :

  Apoptosis; Caspase; CDK; PARP; PROTACs

• Related Pathways :

  Apoptosis; Cell Cycle/DNA Damage; Epigenetics; PROTAC

• Applications :

  Cancer-Kinase/protease

• Field of Research :

  Cancer

• Smiles :

  CC(C)(C1=CN=C(O1)CSC2=CN=C(S2)NC(C3CCN(CC3)C(CCCCCCCN4CC5=C(C4)C=C6C(N(C(C6=C5)=O)C7CCC(NC7=O)=O)=O)=O)=O)C

• Molecular Formula :

  C40H49N7O7S2

• Molecular Weight :

  803.99

• References & Citations :

  [1]Ma L, et al. Discovery of dCDK9-202 as a Highly Potent and Selective PROTAC CDK9 Degrader with Strong In Vivo Antitumor Activity. J Med Chem. 2025 Oct 23;68 (20) :21172-21186.

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• Isoform :

  Caspase 3; Caspase 7; CDK9; Cereblon